Related references
Note: Only part of the references are listed.AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
Justin Cidado et al.
CLINICAL CANCER RESEARCH (2020)
Selective Mediator dependence of cell-type-specifying transcription
Martin G. Jaeger et al.
NATURE GENETICS (2020)
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Laura Cato et al.
CANCER CELL (2019)
Quantification of experimentally induced nucleotide conversions in high-throughput sequencing datasets
Tobias Neumann et al.
BMC BIOINFORMATICS (2019)
Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma
Taylor Hashiguchi et al.
MOLECULAR CANCER THERAPEUTICS (2019)
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
Elizabeth J. Adams et al.
NATURE (2019)
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
Abhijit Parolia et al.
NATURE (2019)
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
Devon R. Blake et al.
SCIENCE SIGNALING (2019)
Pol II phosphorylation regulates a switch between transcriptional and splicing condensates
Yang Eric Guo et al.
NATURE (2019)
Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer sternness activity against non-small-cell lung cancer
Xin Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach
Daniel J. Lee et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Small-molecule targeting of brachyury transcription factor addiction in chordoma
Tanaz Sharifnia et al.
NATURE MEDICINE (2019)
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
Raoul Tibes et al.
FRONTIERS IN ONCOLOGY (2019)
SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo
Shanhu Hu et al.
CANCER RESEARCH (2019)
Next generation CDK2/9 inhibitor CYC065 triggers anaphase catastrophe in diverse aneuploid cancers and markedly inhibits growth and metastasis
Masanori Kawakami et al.
CANCER RESEARCH (2019)
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
Nicholas B. Struntz et al.
CELL CHEMICAL BIOLOGY (2019)
CDK9: A key player in cancer and other diseases
Lia Carolina Franco et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Calla M. Olson et al.
NATURE CHEMICAL BIOLOGY (2018)
CDK9 inhibitors in acute myeloid leukemia
Silvia Boffo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis
Matthias Muhar et al.
SCIENCE (2018)
Mediator and RNA polymerase II clusters associate in transcription-dependent condensates
Won-Ki Cho et al.
SCIENCE (2018)
MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species
Olga Vera-Puente et al.
TRANSLATIONAL RESEARCH (2018)
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Hanghang Zhang et al.
CELL (2018)
Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer
Daphne Brisard et al.
Oncotarget (2018)
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
Georg E. Winter et al.
MOLECULAR CELL (2017)
Transcription control by the ENL YEATS domain in acute leukaemia
Michael A. Erb et al.
NATURE (2017)
An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
M. Ryan Corces et al.
NATURE METHODS (2017)
Thiol-linked alkylation of RNA to assess expression dynamics
Veronika A. Herzog et al.
NATURE METHODS (2017)
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
John E. Bisi et al.
ONCOTARGET (2017)
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
Ulrich Luecking et al.
CHEMMEDCHEM (2017)
YY1 Is a Structural Regulator of Enhancer-Promoter Loops
Abraham S. Weintraub et al.
CELL (2017)
TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib
Wontak Kim et al.
CANCER RESEARCH (2017)
Transcriptional Addiction in Cancer
James E. Bradner et al.
CELL (2017)
Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression
Kenneth M. Felsenstein et al.
ACS CHEMICAL BIOLOGY (2016)
Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile
Zarko V. Boskovic et al.
ACS CHEMICAL BIOLOGY (2016)
Overview of CDK9 as a target in cancer research
Fatima Morales et al.
CELL CYCLE (2016)
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Tinghu Zhang et al.
NATURE CHEMICAL BIOLOGY (2016)
CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression
Partha Mitra et al.
ONCOTARGET (2016)
Persistent androgen receptor addiction in castration-resistant prostate cancer
Michael T. Schweizer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors
Christian Schmidt et al.
NATURE METHODS (2015)
Androgen receptor phosphorylation: biological context and functional consequences
Yulia Koryakina et al.
ENDOCRINE-RELATED CANCER (2014)
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
Chun-Hao Huang et al.
GENES & DEVELOPMENT (2014)
A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein
Marius S. Pop et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Nicholas Kwiatkowski et al.
NATURE (2014)
The cellular thermal shift assay for evaluating drug target interactions in cells
Rozbeh Jafari et al.
NATURE PROTOCOLS (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cyclin-dependent kinases
Marcos Malumbres
GENOME BIOLOGY (2014)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer
Jean Hoffman-Censits et al.
CLINICAL CANCER RESEARCH (2013)
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Shuhui Lim et al.
DEVELOPMENT (2013)
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
T. Karantanos et al.
ONCOGENE (2013)
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Daniel Martinez Molina et al.
SCIENCE (2013)
KLF6 Loss of Function in Human Prostate Cancer Progression Is Implicated in Resistance to Androgen Deprivation
XiaoMei Liu et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Intrinsic disorder in the androgen receptor: identification, characterisation and drugability
Iain J. McEwan
MOLECULAR BIOSYSTEMS (2012)
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
K. C. Goh et al.
LEUKEMIA (2012)
Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
Emma Hornberg et al.
PLOS ONE (2011)
c-Myc Regulates Transcriptional Pause Release
Peter B. Rahl et al.
CELL (2010)
Halogen Bonds Form the Basis for Selective P-TEFb Inhibition by DRB
Sonja Baumli et al.
CHEMISTRY & BIOLOGY (2010)
Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles
Paul A. Clemons et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Genome-Wide Promoter Analysis of the SOX4 Transcriptional Network in Prostate Cancer Cells
Christopher D. Scharer et al.
CANCER RESEARCH (2009)
A small molecule that binds Hedgehog and blocks its signaling in human cells
Benjamin Z. Stanton et al.
NATURE CHEMICAL BIOLOGY (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Small-molecule microarrays as tools in ligand discovery
Arturo J. Vegas et al.
CHEMICAL SOCIETY REVIEWS (2008)
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation
Sonja Baumli et al.
EMBO JOURNAL (2008)
Phosphorylation of the c-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression
Yutaka Hirose et al.
JOURNAL OF BIOCHEMISTRY (2007)
A robust small-molecule microarray platform for screening cell lysates
James E. Bradner et al.
CHEMISTRY & BIOLOGY (2006)
Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate
S Gelmini et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2003)
Share Paper
